Chemotherapy and Radiation Therapy for Lung Cancer
Author Information
Author(s): Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S, Takemoto M, Hiraki Y, Harada M, Tanimoto M
Primary Institution: Okayama University Medical School
Hypothesis
The study aims to evaluate the safety, toxicity, antitumor activity, and survival effects of chemotherapy consisting of docetaxel plus cisplatin with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer.
Conclusion
The combination of docetaxel and cisplatin with radiation therapy showed promising results in treating locally advanced non-small-cell lung cancer.
Supporting Evidence
- 79% of patients responded to the treatment.
- The median survival time was over 23 months.
- Overall survival rates were 76% at 1 year and 54% at 2 years.
- Grade 3 or higher toxicities occurred in 76% of patients.
- Only 14% of patients did not complete radiation therapy.
Takeaway
Doctors tested a new treatment for lung cancer that combines two medicines with radiation, and it helped many patients live longer.
Methodology
Patients received docetaxel and cisplatin on specific days along with radiation therapy, and their responses and side effects were monitored.
Potential Biases
Potential biases may arise from the non-randomized design and the specific patient population selected.
Limitations
The study had a relatively small sample size and was conducted at a single institution.
Participant Demographics
The study included 36 men and 6 women with a median age of 67 years, primarily with stage IIIB lung cancer.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI, 66–91%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website